Center for Research in Antiinfectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, NE 68178, USA.
Curr Pharm Des. 2013;19(2):250-6.
Pathogens that produce extended spectrum β-lactamases (ESBLs), plasmid-mediated AmpC β-lactamases, and carbapenemases may appear falsely susceptible to β-lactam antibiotics in the laboratory. Infected patients may be treated with inappropriate antibiotics if laboratories do not perform accurate tests to detect these resistance mechanisms. Furthermore the resistant pathogens may spread undetected to amplify the therapeutic and infection control challenge. This review makes a case for why and how laboratories should perform tests to detect β-lactamase-mediated resistance in gram-negative pathogens.
产生超广谱β-内酰胺酶(ESBLs)、质粒介导的 AmpC β-内酰胺酶和碳青霉烯酶的病原体在实验室中可能表现出对β-内酰胺类抗生素的虚假敏感性。如果实验室不进行准确的检测来发现这些耐药机制,感染患者可能会被给予不恰当的抗生素治疗。此外,耐药病原体可能会在未被发现的情况下传播,从而加剧治疗和感染控制的挑战。本综述说明了实验室为什么以及如何应该进行检测以发现革兰氏阴性病原体中β-内酰胺酶介导的耐药性。